Results 61 to 70 of about 11,689 (208)
Maximum Systemic Reactogenicity Summary for All Vaccinations.
, 2014 Maximum Systemic Reactogenicity Summary for All Vaccinations.
Julie E. Ledgerwood (253787) +11 more
core +1 more source
Clinical Reactogenicity of Intradermal Bacille Calmette‐Guérin Vaccination [PDF]
Clinical Infectious Diseases, 1999 Clinical, microbiological, and immunologic responses were evaluated in volunteers vaccinated intradermally with bacille Calmette-Guérin (BCG). Most volunteers (98%) developed ulcerative lesions that drained for a mean +/- SE of 4.3 +/- 0.29 weeks. Mycobacterial DNA was detected by a polymerase chain reaction-based amplification technique in biopsy ...
D F, Hoft +7 more
openaire +2 more sources
Journal of Infection and Public HealthBackground: Encouraging annual updated COVID-19 vaccinations for high-risk populations is crucial for public health. However, concerns about significant reactogenicity persist, contributing to vaccine hesitancy.
Hyun Myung Kang +9 more
doaj +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Co‐administration of COVID‐19 and influenza vaccines has been promoted to improve coverage, but acceptance among healthcare workers (HCWs) remains uncertain. In total, 1238 participants were recruited. Participants were categorized by vaccination pattern including same‐day co‐administration, non‐concurrent vaccination, or single vaccine ...
Yu‐Yin Lin +11 more
wiley +1 more source
Эпидемиология и вакцинопрофилактика, 2017 Through the use of trivalent oral poliovirus vaccine made from Sabin strains of types 1, 2, 3 (tOPV), outstanding success of Global polio eradication program has been achieved. Since 1999, wild polio virus type 2 does not circulate in the world.
Yu. H. Khapchaev +6 more
doaj +1 more source
Smart Molecules, EarlyView.This review highlights how chitosan derivatives enhance nanoparticle‐based vaccines through superior stability, mucoadhesion, and immune modulation. By triggering robust mucosal, humoral, and cellular responses, these biocompatible polymers serve as a transformative platform for next‐generation immunotherapeutics and safe and effective vaccine delivery
Sayantani Dasgupta +8 more
wiley +1 more source
Summary of solicited local reactogenicity after prime and boost vaccination.
, 2019 Summary of solicited local reactogenicity after prime and boost vaccination.
Brenda Larkin (736365) +16 more
core +1 more source
Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
Experimental & Molecular Medicine, 2023 AbstractSince the discovery of messenger RNA (mRNA), there have been tremendous efforts to wield them in the development of therapeutics and vaccines. During the COVID-19 pandemic, two mRNA vaccines were developed and approved in record-breaking time, revolutionizing the vaccine development landscape.
Jisun Lee +3 more
openaire +3 more sources
Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe
Acta Paediatrica, EarlyView.ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner +2 more
wiley +1 more source
Maximum local reactogenicity, prime vs boost, by treatment group.
, 2018 Bar graphs show the percentage of participants in each treatment group reporting the specified maximum severity during the reactogenicity period. Left panels (Prime) indicate the maximum severity over all 3 priming injections.
Magdalena E. Sobieszczyk (332353) +18 more
core +1 more source